Rohit Tripathi, VP of Industry Strategy at RELEX, lays out the five signals that he believes can measure if the tariff policy ...

President Trump has reportedly selected White House Domestic Policy Council deputy director Heidi Overton as his nominee for ...

President Trump has reportedly selected White House Domestic Policy Council deputy director Heidi Overton as his nominee for FDA commissioner. LEO Pharma, BioMarin, OmniAb, and Chugai post a busy week ...

Most pharma companies have promising AI pilots. Few have built the conditions to scale them. Here's what separates the ...

Rohit Tripathi, VP of Industry Strategy at RELEX, discusses how pharmaceutical reshoring demands end-to-end capability not ...

Capital continues to flow toward clinical-stage and platform biotech companies, with a wave of new deals, partnerships, and ...

The 340B spread mechanism permits covered entities to retain the difference between discounted acquisition cost and commercial or Medicare reimbursement, incentivizing revenue capture rather than ...

Pharmaceutical Executive releases its 2026 Top 50 company rankings, FDA grants Bristol Myers Squibb's Zenbexus accelerated ...

Exclusive ex-China rights extend to up to 10 partnered biosimilar programs, positioning Sandoz to shape development and registration strategy using early commercial and market-access input. Financial ...

Spherix's VP of market access discusses how the IRA's maximum fair price is reshaping payer strategy, formulary design, and patient out-of-pocket costs far beyond negotiated drugs.

Krieger Scientific's Joseph Morwald explains how siloed departments, disconnected systems, and a lack of cross-functional accountability are creating the structural compliance gaps that FDA warning ...

FDA authorization covers adults ≥50, positioning mFLUSIVA as Moderna’s first mRNA influenza vaccine and expanding its US ...